20-F: Intercure Ltd. Reports Fiscal Year 2023 Results Amidst Regional Challenges

Intercure Ltd. announces its fiscal year 2023 financial results, highlighting revenue of NIS 356 million and Adjusted EBITDA of NIS 53 million, while navigating the impacts of the war in Gaza.

Summary

• Intercure Ltd. reported fiscal year 2023 revenue of NIS 356 million, a 9% decrease compared to the previous year.
• Adjusted EBITDA for 2023 was NIS 53 million, a 31% decrease year-over-year.
• The company experienced a negative cash flow from operations of NIS 54 million in 2023, contrasting with a positive cash flow of NIS 51 million in 2022.
• The war in Gaza significantly impacted the company's Southern Facility, contributing to the financial challenges.
• Intercure is actively seeking compensation from Israeli authorities for damages incurred due to the war.
• The company expanded its pharmacy chain to a total of 29 locations, with 24 actively dispensing medical cannabis.
• Cash and cash equivalents stood at NIS 111 million as of December 31, 2023, down from NIS 246 million the previous year, mainly due to debt repayment.
• The company is preparing to launch products in the German market, leveraging new cannabis legislation.
• A goodwill impairment loss of NIS 63 million was recognized due to the impact of regional events.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reports positive revenue and EBITDA, it also faces significant challenges due to the war in Gaza and other factors. The company is taking steps to address these challenges and capitalize on future opportunities.

Positives

• The company is actively seeking compensation from Israeli authorities for damages incurred due to the war.
• The pharmacy chain expanded to 29 locations, with 24 dispensing medical cannabis.
• The company is preparing to launch products in the German market, leveraging new cannabis legislation.

Negatives

• Revenue decreased by 9% compared to the previous year.
• Adjusted EBITDA decreased by 31% year-over-year.
• The company experienced a negative cash flow from operations.
• The war in Gaza significantly impacted the company's Southern Facility.
• Cash reserves decreased from NIS 246 million to NIS 111 million.
• A goodwill impairment loss of NIS 63 million was recorded.

Risks

• The ongoing war in Gaza and regional instability pose a risk to operations, particularly the Southern Facility.
• Delays in receiving compensation from Israeli authorities could impact financial recovery.
• Regulatory changes and market conditions in the cannabis industry could affect profitability.
• The company faces potential legal proceedings and claims.
• Dependence on key personnel and the ability to attract and retain qualified employees are crucial.
• Cybersecurity threats and data breaches could disrupt operations and harm reputation.
• Fluctuations in foreign exchange rates may impact financial results.

Future Outlook

The company plans to launch products in the German market and is working to restore its Southern Facility. The company is also focused on expanding its global footprint and diversifying its production capabilities.

Industry Context

The announcement reflects the challenges faced by companies in the cannabis industry due to regulatory changes, market competition, and geopolitical events. The company is adapting its strategies to navigate these challenges and capitalize on opportunities in emerging markets.

Comparison to Industry Standards

• The company competes with other licensed producers of pharmaceutical-grade cannabis and cannabis-based products in Israel, such as Breath Of Life Pharma, Ltd. and IM Cannabis Corp., Village farms Crop, Cronos Group.
• The company also competes with local licensed producers in fully regulated jurisdictions, such as European Union member states, and licensed producers in Canada who market their products in the medical-use market, such as Bedrocan International B.V. and Aurora Cannabis Inc.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit with Cann Pharmaceutical Ltd. regarding a terminated acquisition agreement.
• The company is involved in a lawsuit with minority shareholders of Cannolam.
• The company is involved in a lawsuit with Geffen Residence & Renewal Ltd. regarding a purchase agreement.

Related Party Transactions

• The company has a sublease agreement with companies related to a related party, Mr. Alexander Rabinovich.
• The company has loans from related parties.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the ongoing legal proceedings.
• Employees may be impacted by the company's restructuring efforts and the impact of the war in Gaza.
• Customers may be impacted by the availability and quality of the company's products.

Next Steps

• Restore the Southern Facility.
• Obtain compensation from Israeli authorities for war-related damages.
• Launch products in the German market.
• Continue to expand global footprint and diversify production capabilities.

Key Dates

Keywords

Intercure, cannabis, medical cannabis, financial results, EBITDA, revenue, pharmacy, Israel, war in Gaza, Southern Facility, German market, compensation, goodwill impairment